Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 10680 matches for

Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.

Histology and magnetic resonance images from a mouse with breast cancer brain metastases, injected intravenously 2 hours previously with a TNFR1-selective mutant TNF protein. 3 items in the picture: Cresyl violet stained brain section showing location of a micrometastasis. Adjacent brain section stained with Hanker-Yates demonstrates HRP extravasation (brown staining) and, hence, BBB breakdown selectively at the site of metastasis. Post-contrast (gadolinium-DTPA) image from the same mouse showing extravasation of contrast at the metastatic site (hyperintensity) confirming local BBB breakdown. Note, the BBB remains intact in the rest of the brain.
Figure caption: Histology and magnetic resonance images from a mouse with breast cancer brain metastases, injected intravenously 2 hours previously with a TNFR1-selective mutant TNF protein. (A) Cresyl violet stained brain section showing location of a micrometastasis (boxed region and inset). (B) Adjacent brain section stained with Hanker-Yates demonstrates HRP extravasation (brown staining) and, hence, BBB breakdown selectively at the site of metastasis. (C) Post-contrast (gadolinium-DTPA) image from the same mouse showing extravasation of contrast at the metastatic site (hyperintensity) confirming local BBB breakdown. Note, the BBB remains intact in the rest of the brain.

Molecular Diagnostics Centre

An ISO-accredited research facility specialising in the next generation sequencing of liquid biopsies

MCHUGH GROUP

Studying DNA damage and repair to understand the causes of cancer and improve its treatment.

HIGGINS GROUP

Tumour Radiosensitivity

HAMMOND GROUP

Tumour Hypoxia

SCHUH GROUP

Oxford Molecular Diagnostics

FAIRFAX GROUP

Genomics of Inflammation and Cancer Immunology

SIBSON GROUP

Experimental Neuroimaging

GLEESON GROUP

Novel Clinical Imaging Research

TARSOUNAS GROUP

Genome Stability and Tumourigenesis

VALLIS GROUP

Experimental Radiotherapeutics

OLCINA GROUP

Immune Radiation Biology

SEYMOUR GROUP

Anticancer Viruses and Cancer Vaccines

MIDDLETON GROUP

Early Phase Clinical Trials & Melanoma Therapy

BLAGDEN GROUP

Cancer Therapeutics and mRNA Dysregulation

Translational Histopathology

KERR GROUP

Adjuvant Colorectal Cancer

BODMER GROUP

Cancer and Immunogenetics

O'NEILL GROUP

LA THANGUE GROUP

Cancer Cell Cycle

Mechanical Workshop

The Mechanical Workshop delivers an on-site fabrication facility for custom-made, precision mechanical items for use in scientific research.

Load More

Similar stories

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Subashan Vadibeler wins 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Gulnar Abdullayeva receives an Azerbaijan Presidential Award for Youth 2024

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.